Education
About Us
Working with TipRanks
Follow Us
Leap Therapeutics Inc (LPTX)
NASDAQ:LPTX
LPTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.31 - $4.79
Previous CloseN/A
Volume72.74K
Average Volume (3M)3.96M
Market Cap
$13.06M
Enterprise Value$71.62M
Total Cash (Recent Filing)$15.98M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.41
Next Earnings
May 19, 2025EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding41,257,603
10 Day Avg. Volume11,318,087
30 Day Avg. Volume3,963,178
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market Cap5.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.02
Forecast
1Y Price Target
$3.00Price Target Upside837.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Leap Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Market PotentialPromising efficacy data point to market potential of DNK-01 in approximately 25%-50% of 2L patients.
Regulatory PathwayManagement believes the data in CRC is strong enough to initiate a conversation with FDA to seek a regulatory pathway based on the positive objective response data in DeFianCe.
Treatment EfficacyEncouraging data in a niche CRC population showed a higher objective response rate for sirexatamab compared to the control group.
Bears Say
Clinical Trial ResultsSirexatamab did not show benefit in GEJ/G cancer, lowering the overall market potential of the drug.
Financial PositionThe company's current cash position is insufficient to fund a Phase 3 clinical program, indicating a potential need for partnership.
Pipeline DevelopmentThere are uncertainties regarding the company’s pipeline development and lack of meaningful catalysts.
---
Ownership Overview
6.24% Insiders
3.88% Mutual Funds
38.53% Other Institutional Investors
45.66% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LPTX FAQ
What was Leap Therapeutics Inc’s price range in the past 12 months?
Leap Therapeutics Inc lowest stock price was $0.30 and its highest was $4.79 in the past 12 months.
What is Leap Therapeutics Inc’s market cap?
Leap Therapeutics Inc’s market cap is $13.06M.
When is Leap Therapeutics Inc’s upcoming earnings report date?
Leap Therapeutics Inc’s upcoming earnings report date is May 19, 2025 which is in 48 days.
How were Leap Therapeutics Inc’s earnings last quarter?
Leap Therapeutics Inc released its earnings results on Mar 26, 2025. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.415 by $0.045.
Is Leap Therapeutics Inc overvalued?
According to Wall Street analysts Leap Therapeutics Inc’s price is currently Undervalued.
Does Leap Therapeutics Inc pay dividends?
Leap Therapeutics Inc does not currently pay dividends.
What is Leap Therapeutics Inc’s EPS estimate?
Leap Therapeutics Inc’s EPS estimate is -0.39.
How many shares outstanding does Leap Therapeutics Inc have?
Leap Therapeutics Inc has 41,257,603 shares outstanding.
What happened to Leap Therapeutics Inc’s price movement after its last earnings report?
Leap Therapeutics Inc reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.415. Following the earnings report the stock price went up 15.385%.
Which hedge fund is a major shareholder of Leap Therapeutics Inc?
Currently, no hedge funds are holding shares in LPTX
---
Leap Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (837.50% Upside)
$3.00 (837.50% Upside)
Blogger Sentiment
Bullish
LPTX Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $18.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.1%
Last 30 Days ▲ 10.1%
Last 30 Days ▲ 10.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.12%
12-Months-Change
Fundamentals
Return on Equity
-141.94%
Trailing 12-Months
Asset Growth
-32.55%
Trailing 12-Months
Company Description
Leap Therapeutics Inc
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
---
LPTX Stock 12 Month Forecast
Average Price Target
$3.00
▲(837.50% Upside)
Technical Analysis
Carisma Therapeutics
―
MetaVia
―
Citius Pharmaceuticals
―
Athira Pharma
―
Sensei Biotherapeutics
―
Best Analysts Covering LPTX
1 Year
1 Year Success Rate
0/10 ratings generated profit
1 Year Average Return
-40.97%
assigned a buy rating 2 months ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -40.97% per trade.
---